“But why are they calling these products ‘drugs?’” I asked at the recent CMC Strategy meeting that CaSSS hosted in Gaithersburg. “Well it’s because they aren’t vaccines or blood products” said an old friend, who is an authority in the field. “But,” I said, “we’re really talking about therapeutic glyco-proteins produced by living organisms.” And just to make sure I was remembering things correctly, I searched Google and reviewed the definitions for a “biologic” and “biological” in several of the top technical references. Truly, a biologic or biological is a substance produced by a living organism, which would include glyco-proteins, non-glycosylated proteins, enzymes, viruses, and broken up proteins which could be used as poly-peptides or simple antigens…
Tag: <span>small-molecule drugs</span>
For decades, recombinant genes have been expressed in a variety of cellular systems to generate protein reagents that are the potential targets for new small-molecule drugs. As these targets become more complex, researchers have developed innovative methods to study the structure of these proteins and their interactions with potential drugs. BioExpress® 2000 media (Cambridge Isotope Laboratories, CIL) incorporates isotope-labeled amino acids
into recombinant proteins expressed in baculovirus-infected insect cells to assist nuclear magnetic resonance (NMR) structural studies. In order to use this labeled media most efficiently, expression conditions must be optimized at a small-scale prior to production…
